1. Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax

   • Madeline Waldron
   • Allison Winter
   • Brian T. Hill

   Review Article 25 March 2017 Pages: 1255 - 1266

   

2. Levetiracetam Clinical Pharmacokinetic Monitoring in Pediatric Patients with Epilepsy

   • Jason Tan
   • Vanessa Paquette
   • Mary H. H. Ensom

   Review Article 28 March 2017 Pages: 1267 - 1285

3. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab

   • Maria Rosario
   • Nathanael L. Dirks
   • Irving Fox

   Review Article Open access 18 May 2017 Pages: 1287 - 1301

   

4. Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy

   • André Dallmann
   • Ibrahim Ince
   • Georg Hempel

   Systematic Review 11 April 2017 Pages: 1303 - 1330

   

5. Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects

   • Dymphy R. H. Huntjens
   • Sivi Ouwerkerk-Mahadevan
   • Rene Verloes

   Original Research Article 25 February 2017 Pages: 1331 - 1342

   

6. Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data

   • Christoph P. Hornik
   • Huali Wu
   • Daniel Gonzalez

   Original Research Article 13 March 2017 Pages: 1343 - 1353

   

7. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling

   • Neeraj Gupta
   • Paul M. Diderichsen
   • Karthik Venkatakrishnan

   Original Research Article Open access 13 March 2017 Pages: 1355 - 1368

   

8. A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon α-2a in Hepatitis C Patients

   • Mohammad I. Saleh

   Original Research Article 10 April 2017 Pages: 1369 - 1379

   

9. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment

   • Thomas C. Marbury
   • Anne Flint
   • Kenneth Lasseter

   Original Research Article Open access 27 March 2017 Pages: 1381 - 1390

   

10. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects

    • Helene Hausner
    • Julie Derving Karsbøl
    • Thomas W. Anderson

    Original Research Article Open access 27 March 2017 Pages: 1391 - 1401

    

11. Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy

    • Andreas Lindauer
    • Christian Laveille
    • Armel Stockis

    Original Research Article Open access 13 March 2017 Pages: 1403 - 1413

    

12. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide

    • Amparo de la Peña
    • Xuewei Cui
    • Corina Loghin

    Original Research Article 29 March 2017 Pages: 1415 - 1427